Causal claim
Fda Regulatory U Turn UniqureThe two move together: more cause, more effect. The map scores it at 30% confidence, weighed from 1 article.
Regulatory reversal reopens pathway for uniQure to refile its BLA for its previously rejected gene therapy
Nothing upstream on the map yet.